Sarah Wall, MD
Hematology · Columbus, OHNPI 1174815708
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,225 of the $33,440 with a category attached, or 72.4%. 12 manufacturers reported payments, led by Sobi, Inc at 42.6% of the total. Reporting peaked in 2024 at $18,028 and has fallen 78.0% since, to $3,958 in 2025.
Across 31 payments — averaging $1078.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sobi, Inc$14K
- CTI Biopharma Corp.$7K
- Autolus Inc$3K
- E.r. Squibb & Sons, L.L.C.$3K
- National Marrow Donor Program$2K
- Bristol Myers Squibb$2K
- plus $2K from 6 others
Across 62 payments — averaging $12,240 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$366K
- Stemline Therapeutics Inc.$147K
- Sobi, Inc$83K
- CSL Behring$81K
- CTI Biopharma Corp.$40K
- Incyte Corporation$24K
- plus $18K from 1 others
What the payments were for
- Consulting fees$4,50813%
- Speaking & faculty fees$24,22572%
- Travel & lodging$1,4644%
- Food & beverage$3,23010%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sobi, Inc | 8 | $14,243 |
| CTI Biopharma Corp. | 3 | $6,681 |
| Autolus Inc | 2 | $3,338 |
| E.r. Squibb & Sons, L.L.C. | 1 | $2,768 |
| National Marrow Donor Program | 6 | $2,388 |
| Bristol Myers Squibb | 3 | $1,804 |
| Morphosys, US Inc. | 2 | $1,798 |
| Jazz Pharmaceuticals Inc. | 2 | $253 |
| Medexus Pharma, Inc. | 1 | $84 |
| Iovance Biotherapeutics, Inc. | 1 | $48 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $23 |
| Pharmaessentia USA Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,440 in reported general payments places this provider in the 75th percentile of 84 hematology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 157 | $2,505,164 |
| OjjaaraMomelotinib Dihydrochloride | 53 | $1,471,715 |
| RezurockBelumosudil Mesylate | 47 | $1,302,577 |
| ScemblixAsciminib Hydrochloride | 12 | $250,756 |
| IclusigPonatinib Hcl | 11 | $237,992 |
| Budesonide EcBudesonide | 11 | $1,210 |
| Acyclovir | 16 | $554 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $48 |
Paid to pharmacies, not to this prescriber.
Other hematology in Columbus
- Uma BorateColumbus$323K
- Sam PenzaColumbus$256K
- Spero CatalandColumbus$245K
- Kami MaddocksColumbus$236K
- Narendranath EpperlaColumbus$199K
- Yvonne EfeberaColumbus$169K
- Naresh BummaColumbus$109K
- Kerry RogersColumbus$100K
- Jennifer WoyachColumbus$73K
- Hannah ChoeColumbus$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.